Player FM ऐप के साथ ऑफ़लाइन जाएं!
Top Cardiology Trials of 2022
Manage episode 350486483 series 2794871
Trials on heart failure, hypertension and lipid-lowering drugs, and the evolution of antithrombin and antiplatelet therapy are discussed in part 2 of cardiologists Bob Harrington and Mike Gibson's annual review.
This podcast is intended for healthcare professionals only.
To read a transcript or to comment, visit
https://www.medscape.com/author/bob-harrington
Lipid Lowering
Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure (STRONG-HF): A Multinational, Open-Label, Randomised, Trial
https://doi.org/10.1016/S0140-6736(22)02076-1
Why Combination Lipid-Lowering Therapy Should Be Considered Early in the Treatment of Elevated LDL-C for CV Risk Reduction
Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-gated Chest CTs to Improve Statin Rates (NOTIFY-1 Project)
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062746
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
https://doi.org/10.1016/j.jacc.2022.09.021
Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers
https://doi.org/10.1016/j.jacc.2022.10.013
Antihypertensive Drugs
No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF
https://www.medscape.com/viewarticle/983611
Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events
www.nejm.org/doi/full/10.1056/NEJMoa2212270
Antiplatelets
Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention in Patients at High Bleeding Risk: A MASTER DAPT Trial Sub-analysis
https://doi.org/10.1093/eurheartj/ehac284
PANTHER: Should Clopidogrel Become the 'New Aspirin' in CAD?
https://www.medscape.com/viewarticle/980117
P2Y12 Inhibitor Versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-analysis of Randomized Trials
https://doi.org/10.1093/ehjopen/oeac019
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes
https://doi.org/10.1056/nejmoa0904327
TCT-320 Pharmacokinetic and Pharmacodynamic Profile of PL-ASA, a Novel Phospholipid-Aspirin Complex Liquid Formulation, Compared to Enteric-Coated Aspirin at an 81-mg Dose – Results From a Prospective, Randomized, Crossover Study
https://www.jacc.org/doi/10.1016/j.jacc.2021.09.1173
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
https://europepmc.org/article/pmc/pmc8773391
Antithrombins/Factor XI
Rivaroxaban in Patients With a Recent Acute Coronary Syndrome
https://www.nejm.org/doi/full/10.1056/nejmoa1112277
Genetically Determined FXI (Factor XI) Levels and Risk of Stroke
https://doi.org/10.1161/strokeaha.118.022792
Factor XIa Inhibition With Asundexian After Acute Non-cardioembolic Ischaemic Stroke (PACIFIC-Stroke): an International, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial
https://doi.org/10.1016/s0140-6736(22)01588-4
Safety of the Oral Factor Xia Inhibitor Asundexian Compared With Apixaban in Patients With Atrial Fibrillation (PACIFIC-AF): a Multicentre, Randomised, Double-Blind, Double-Dummy, Dose-Finding Phase 2 Study
https://doi.org/10.1016/S0140-6736(22)00456-1
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
https://doi.org/10.1161/circulationaha.122.061612
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology
https://www.medscape.com/twic
Questions or feedback? Please contact
news@medscape.net
64 एपिसोडस
Manage episode 350486483 series 2794871
Trials on heart failure, hypertension and lipid-lowering drugs, and the evolution of antithrombin and antiplatelet therapy are discussed in part 2 of cardiologists Bob Harrington and Mike Gibson's annual review.
This podcast is intended for healthcare professionals only.
To read a transcript or to comment, visit
https://www.medscape.com/author/bob-harrington
Lipid Lowering
Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure (STRONG-HF): A Multinational, Open-Label, Randomised, Trial
https://doi.org/10.1016/S0140-6736(22)02076-1
Why Combination Lipid-Lowering Therapy Should Be Considered Early in the Treatment of Elevated LDL-C for CV Risk Reduction
Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-gated Chest CTs to Improve Statin Rates (NOTIFY-1 Project)
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062746
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
https://doi.org/10.1016/j.jacc.2022.09.021
Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers
https://doi.org/10.1016/j.jacc.2022.10.013
Antihypertensive Drugs
No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF
https://www.medscape.com/viewarticle/983611
Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events
www.nejm.org/doi/full/10.1056/NEJMoa2212270
Antiplatelets
Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention in Patients at High Bleeding Risk: A MASTER DAPT Trial Sub-analysis
https://doi.org/10.1093/eurheartj/ehac284
PANTHER: Should Clopidogrel Become the 'New Aspirin' in CAD?
https://www.medscape.com/viewarticle/980117
P2Y12 Inhibitor Versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-analysis of Randomized Trials
https://doi.org/10.1093/ehjopen/oeac019
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes
https://doi.org/10.1056/nejmoa0904327
TCT-320 Pharmacokinetic and Pharmacodynamic Profile of PL-ASA, a Novel Phospholipid-Aspirin Complex Liquid Formulation, Compared to Enteric-Coated Aspirin at an 81-mg Dose – Results From a Prospective, Randomized, Crossover Study
https://www.jacc.org/doi/10.1016/j.jacc.2021.09.1173
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
https://europepmc.org/article/pmc/pmc8773391
Antithrombins/Factor XI
Rivaroxaban in Patients With a Recent Acute Coronary Syndrome
https://www.nejm.org/doi/full/10.1056/nejmoa1112277
Genetically Determined FXI (Factor XI) Levels and Risk of Stroke
https://doi.org/10.1161/strokeaha.118.022792
Factor XIa Inhibition With Asundexian After Acute Non-cardioembolic Ischaemic Stroke (PACIFIC-Stroke): an International, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial
https://doi.org/10.1016/s0140-6736(22)01588-4
Safety of the Oral Factor Xia Inhibitor Asundexian Compared With Apixaban in Patients With Atrial Fibrillation (PACIFIC-AF): a Multicentre, Randomised, Double-Blind, Double-Dummy, Dose-Finding Phase 2 Study
https://doi.org/10.1016/S0140-6736(22)00456-1
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
https://doi.org/10.1161/circulationaha.122.061612
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology
https://www.medscape.com/twic
Questions or feedback? Please contact
news@medscape.net
64 एपिसोडस
सभी एपिसोड
×प्लेयर एफएम में आपका स्वागत है!
प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।